Japanese Pediatric H5N1 Vaccine Study

An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Pediatric Population Aged 6 Months to 17 Years

The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese pediatric population aged 6 months to 17 years

Study Overview

• Status: Completed
• Conditions: Influenza
• Intervention / Treatment: Biological: H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Phase 3

Contacts and Locations

Study Locations

• Japan
  • Kagoshima-ken
    • Kagoshima-shi, Kagoshima-ken, Japan, 890-0063
      • Minami Clinic
    • Kagoshima-shi, Kagoshima-ken, Japan, 890-0082
      • Shibahara Tahara Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 months to 17 years (Child)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Participant is 6 months to 17 years old at time of screening.
• Participant is born at full term of pregnancy (≥37 weeks) with a birth weight ≥2 kg (for participants aged 6 to 35 months only).
• Participant is generally healthy, as determined by investigator's clinical judgment through collection of medical history and a physical examination.
• If female of childbearing potential, participant has a negative pregnancy test within 24 hours prior to first scheduled vaccination and agrees to employ adequate birth control measures for study duration.
• Participant and/or their parents/legal guardians is/are willing and able to comply with protocol requirements.

Exclusion Criteria:

• Participant has a history of exposure to H5N1 virus or a history of vaccination with an H5N1 influenza vaccine.
• Participant is at high risk of contracting H5N1 influenza infection (e.g. contact with poultry).
• Participant currently has or has a history of a significant cardiovascular (including hypertension), respiratory (including asthma), metabolic, neurological (including Guillain-Barré Syndrome and acute disseminated encephalomyelitis), hepatic, rheumatic, autoimmune, hematological, gastrointestinal or renal disorder.
• Participant has any inherited or acquired immunodeficiency

• Participant has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to:

  • systemic or inhaled corticosteroids
  • radiation treatment
  • or other immunosuppressive or cytotoxic drugs.
• Participant has a history of severe allergic reactions or anaphylaxis.
• Participant has a rash, dermatological condition or tattoos which may interfere with injection site reaction rating.
• Participant has received a blood transfusion, immunoglobulins or other blood derivatives within 90 days prior to study entry.
• Participant has donated blood or plasma within 30 days prior to study entry.
• Participant has received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study.
• Participant has a functional or surgical asplenia.
• Participant has a known or suspected problem with alcohol or drug abuse.
• Participant has been exposed to an investigational product (IP) within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
• Participant is a family member or employee of the investigator.
• Participant is pregnant or lactating at the time of enrollment.
• Participant has any other condition that disqualifies his/her participation in the study in the opinion of the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Influenza Vaccine; One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection on Day 1 and 22	Biological: H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Co-Primary Evaluation of Immunogenicity by Single Radial Hemolysis (SRH) Assay: Number of participants with antibody response to vaccine strain (A/Indonesia/05/2005)	Associated with protection 21 days after second vaccination defined as hemolysis area measured by SRH assay ≥25mm^2	Day 43
Co-Primary Evaluation of Immunogenicity by SRH Assay: Number of participants demonstrating seroconversion 21 days after the second vaccination	'Seroconversion' is defined as either a ≥25mm^2 hemolysis area after the vaccination in case of a negative prevaccination sample (≤4mm^2) or a ≥50% increase in hemolysis area if the prevaccination sample is >4mm^2.	Day 43
Co-Primary Evaluation of Immunogenicity by SRH Assay: Fold increase of antibody response 21 days after the second vaccination as compared to baseline		Day 43

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of Immunogenicity by SRH Assay: Number of participants with antibody response to the vaccine strain (A/Indonesia/05/2005)	Associated with protection 21 days after the first and 180 days after the second vaccination defined as SRH area ≥25mm^2	Days 22 and 202
Evaluation of Immunogenicity by SRH Assay: Number of participants demonstrating seroconversion 21 days after the first and 180 days after the second vaccination	'Seroconversion' is defined as either a ≥25mm^2 hemolysis area after the vaccination in case of a negative prevaccination sample [≤4mm^2] or a ≥50% increase in hemolysis area if the prevaccination sample is >4mm^2.	Days 22 and 202
Evaluation of Immunogenicity by SRH Assay: Antibody response 21 days after the first and 21 and 180 days after the second vaccination		Days 22, 43 and 202
Evaluation of Immunogenicity by SRH Assay: Fold increase of antibody response 21 days after the first and 180 days after the second vaccination as compared to baseline		Days 22 and 202
Evaluation of Immunogenicity by Microneutralization (MN) Assay: Number of participants with antibody response to the vaccine strain (A/Indonesia/05/2005)	Associated with protection 21 days after the first and 21 and 180 days after the second vaccination defined as MN titer ≥ 1:20	Days 22, 43 and 202
Evaluation of Immunogenicity by MN Assay: Number of participants demonstrating seroconversion 21 days after the first and 21 and 180 days after the second vaccination	'Seroconversion' is defined as a four-fold or greater increase in titer as compared to baseline.	Days 22, 43 and 202
Evaluation of Immunogenicity by MN Assay: Number of participants demonstrating either ≥4-fold titer increase compared to baseline if above detection limit OR a ≥ 20 titer after vaccination if baseline titer is below detection limit		Days 22, 43 and 202
Evaluation of Immunogenicity by MN Assay: Antibody response 21 days after the first and 21 and 180 days after the second vaccination		Days 22, 43 and 202
Evaluation of Immunogenicity by MN Assay: Fold increase of antibody response 21 days after the first and 21 and 180 days after the second vaccination as compared to baseline		Days 22, 43 and 202
Evaluation of Immunogenicity by Hemagglutination Inhibition (HI) Assay: Number of participants with antibody response to the vaccine strain (A/Indonesia/05/2005)	Associated with protection 21 days after the first and 21 and 180 days after second vaccination defined as HI titer ≥ 1:40	Days 22, 43 and 202
Evaluation of Immunogenicity by HI Assay: Number of participants demonstrating seroconversion 21 days after the first and 21 and 180 days after the second vaccination	'Seroconversion' is defined as a 4-fold or greater increase in HI titer as compared to baseline	Days 22, 43 and 202
Evaluation of Immunogenicity by HI Assay: Antibody response 21 days after the first and 21 and 180 days after the second vaccination		Days 22, 43 and 202
Evaluation of Immunogenicity by HI Assay: Fold increase of antibody response 21 days after the first and 21 and 180 days after the second vaccination as compared to baseline		Days 22, 43 and 202
Frequency and severity of injection site and systemic reactions until 21 days after the first and second vaccinations		Through study day 43
Number of participants with fever, malaise or shivering (in children and adolescents aged 3 to 17 years) and fever and irritability (in infants and young children aged 6 to 35 months) with onset within 7 days after the first and second vaccinations.		Days 1-7 and days 22-28
Frequency and severity of all adverse events (AEs) observed during the entire study period		Through day 202

Collaborators and Investigators

• Sponsor: Ology Bioservices
• Collaborators: Baxter Innovations GmbH
• Investigators: Study Director: Nirjhar Chatterjee, MD, Baxter Innovations GmbH

Study record dates

Study Major Dates

• Study Start: August 1, 2013
• Primary Completion (Actual): November 1, 2013
• Study Completion (Actual): April 1, 2014

Study Registration Dates

• First Submitted: July 26, 2013
• First Submitted That Met QC Criteria: July 26, 2013
• First Posted (Estimate): July 30, 2013

Study Record Updates

• Last Update Posted (Estimate): October 9, 2015
• Last Update Submitted That Met QC Criteria: October 7, 2015
• Last Verified: May 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Orthomyxoviridae Infections; Influenza, Human
• Other Study ID Numbers: 811202